Abeona therapeutics announces strategy update and 2021 financial results

Eb-101 pivotal phase 3 viital™ study in rdeb achieves target enrollment; top-line data expected in third quarter of 2022; gained fda alignment on cmc requirements for eb-101 including characterization and validation plans
ABEO Ratings Summary
ABEO Quant Ranking